Phase I study of a novel therapeutic vaccine as perioperative treatment for patients with surgically resectable hepatocellular carcinoma: The YCP02 trial

Aim Developing effective adjuvant therapies is essential for improving the surgical outcomes in patients with hepatocellular carcinoma (HCC). Immunotherapy against HCC has become a promising strategy; however, only approximately 30% of all HCC patients respond to immunotherapy. Previously, we genera...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hepatology research 2023-07, Vol.53 (7), p.649-660
Hauptverfasser:	Nakajima, Masao, Hazama, Shoichi, Tokumitsu, Yukio, Shindo, Yoshitaro, Matsui, Hiroto, Matsukuma, Satoshi, Nakagami, Yuki, Tamada, Koji, Udaka, Keiko, Sakamoto, Michiie, Saito, Akira, Kouki, Yasunari, Uematsu, Toshinari, Xu, Ming, Iida, Michihisa, Tsunedomi, Ryouichi, Suzuki, Nobuaki, Takeda, Shigeru, Ioka, Tatsuya, Doi, Shun, Nagano, Hiroaki
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens Apoptosis CD8 antigen Heat shock proteins Heparan sulfate proteoglycans Hepatocellular carcinoma Histocompatibility antigen HLA hLAG‐3Ig plus poly‐ICLC Hsp70 protein Immunization Immunohistochemistry Immunotherapy Infiltration Leukocytes Liver cancer Lymphocytes T Metastases Patients peptide vaccination therapy Surgery Surgical outcomes tumor immunogenicity Tumors Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!